miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients

Breast Cancer Research and Treatment

Volumn 160, Issue 3, 2016, Pages 439-446

  Lánczky, András ^a   Nagy, Ádám ^a,b   Bottai, Giulia ^c   Munkácsy, Gyöngyi ^a   Szabó, András ^b   Santarpia, Libero ^c   Győrffy, Balázs ^a,b  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Biomarkers; Breast cancer; Gene expression; MicroRNAs; Prognosis; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MICRORNA; MICRORNA 101; MICRORNA 29C; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESEARCH; CANCER SURVIVAL; DATA ANALYSIS; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC DATABASE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIR 101 GENE; MIR 29C GENE; ONLINE SYSTEM; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RNA ANALYSIS; VALIDATION STUDY; BIOLOGY; BREAST TUMOR; COMPUTER INTERFACE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MORTALITY; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; SOFTWARE; WEB BROWSER;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SOFTWARE; USER-COMPUTER INTERFACE; WEB BROWSER;

EID: 84991320279     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-016-4013-7     Document Type: Article

References (32)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386. doi:10.1002/ijc.29210
2. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206–2223. doi:10.1093/annonc/mdt303
3. Dowsett M, Dunbier AK (2008) Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14:8019–8026. doi:10.1158/1078-0432.CCR-08-0974
4. Iorio MV, Croce CM (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4:143–159. doi:10.1002/emmm.201100209
5. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavaré S, Caldas C, Miska EA (2007) MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8:R214. doi:10.1186/gb-2007-8-10-r214
6. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65:7065–7070. doi:10.1158/0008-5472.CAN-05-1783
7. Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL, Ragoussis J (2011) microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res 71:5635–5645. doi:10.1158/0008-5472.CAN-11-0489
8. Volinia S, Croce CM (2013) Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci USA 110:7413–7417. doi:10.1073/pnas.1304977110
9. van Schooneveld E, Wildiers H, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ (2015) Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res 17:21. doi:10.1186/s13058-015-0526-y
10. Bertoli G, Cava C, Castiglioni I (2015) MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics 5:1122–1143. doi:10.7150/thno.11543
11. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70. doi:10.1038/nature11412
12. Dvinge H, Git A, Gräf S, Salmon-Divon M, Curtis C, Sottoriva A, Zhao Y, Hirst M, Armisen J, Miska EA, Chin SF, Provenzano E, Turashvili G, Green A, Ellis I, Aparicio S, Caldas C (2013) The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 497:378–382. doi:10.1038/nature12108
13. de Rinaldis E, Gazinska P, Mera A, Modrusan Z, Fedorowicz GM, Burford B, Gillett C, Marra P, Grigoriadis A, Dornan D, Holmberg L, Pinder S, Tutt A (2013) Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. BMC Genom 23(14):643. doi:10.1186/1471-2164-14-643
14. Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Rønneberg JA, Johnsen H, Navon R, Rødland E, Mäkelä R, Naume B, Perälä M, Kallioniemi O, Kristensen VN, Yakhini Z, Børresen-Dale AL (2011) miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One 6:e16915. doi:10.1371/journal.pone.0016915
15. Santarpia L, Bottai G, Kelly CM, Győrffy B, Székely B, Pusztai L (2016) Deciphering and targeting oncogenic mutations and pathways in breast cancer. Oncologist 21:1063–1078. doi:10.1634/theoncologist.2015-0369
16. Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat 123:725–731. doi:10.1007/s10549-009-0674-9
17. Gyorffy B, Lánczky A, Szállási Z (2012) Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer 19:197–208. doi:10.1530/ERC-11-0329
18. Győrffy B, Surowiak P, Budczies J, Lánczky A (2013) Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One 8:e82241. doi:10.1371/journal.pone.0082241
19. Okada Y, Muramatsu T, Suita N, Kanai M, Kawakami E, Iotchkova V, Soranzo N, Inazawa J, Tanaka T (2016) Significant impact of miRNA-target gene networks on genetics of human complex traits. Sci Rep 6:22223. doi:10.1038/srep22223
20. Chen X, Yan CC, Zhang X, You ZH, Deng L, Liu Y, Zhang Y, Dai Q (2016) WBSMDA: within and between score for MiRNA-disease association prediction. Sci Rep 6:21106. doi:10.1038/srep21106
21. Meng F, Wang J, Dai E, Yang F, Chen X, Wang S, Yu X, Liu D, Jiang W (2016) Psmir: a database of potential associations between small molecules and miRNAs. Sci Rep 6:19264. doi:10.1038/srep19264
22. Kleivi Sahlberg K, Bottai G, Naume B, Burwinkel B, Calin GA, Børresen-Dale AL, Santarpia L (2015) A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. Clin Cancer Res 21:1207–1214. doi:10.1158/1078-0432.CCR-14-2011
23. De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L (2015) MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget 6:37269–37280. doi:10.18632/oncotarget.5495
24. Parrella P, Barbano R, Pasculli B, Fontana A, Copetti M, Valori VM, Poeta ML, Perrone G, Righi D, Castelvetere M, Coco M, Balsamo T, Morritti M, Pellegrini F, Onetti-Muda A, Maiello E, Murgo R, Fazio VM (2014) Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients. Mol Cancer 13:142. doi:10.1186/1476-4598-13-142
25. Chen B, Tang H, Liu X, Liu P, Yang L, Xie X, Ye F, Song C, Xie X, Wei W (2015) miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer. Cancer Lett 356:410–417. doi:10.1016/j.canlet.2014.09.028
26. Gee HE, Camps C, Buffa FM, Colella S, Sheldon H, Gleadle JM, Ragoussis J, Harris AL (2008) MicroRNA-10b and breast cancer metastasis. Nature 455:E8–E9. doi:10.1038/nature07362
27. Pandey AK, Zhang Y, Zhang S, Li Y, Tucker-Kellogg G, Yang H, Jha S (2015) TIP60-miR-22 axis as a prognostic marker of breast cancer progression. Oncotarget 6:41290–41306. doi:10.18632/oncotarget.5636
28. Song SJ, Poliseno L, Song MS, Ala U, Webster K, Ng C, Beringer G, Brikbak NJ, Yuan X, Cantley LC, Richardson AL, Pandolfi PP (2013) MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 154:311–324. doi:10.1016/j.cell.2013.06.026
29. Gyorffy B, Gyorffy A, Tulassay Z (2005) The problem of multiple testing and solutions for genome-wide studies. Orv Hetil 146:559–563
30. Antonov AV, Knight RA, Melino G, Barlev NA, Tsvetkov PO (2013) MIRUMIR: an online tool to test microRNAs as biomarkers to predict survival in cancer using multiple clinical data sets. Cell Death Differ 20:367. doi:10.1038/cdd.2012.137
31. Goswami CP, Nakshatri H (2012) PROGmiR: a tool for identifying prognostic miRNA biomarkers in multiple cancers using publicly available data. J Clin Bioinform 2:23. doi:10.1186/2043-9113-2-23
32. Aguirre-Gamboa R, Trevino V (2014) SurvMicro: assessment of miRNA-based prognostic signatures for cancer clinical outcomes by multivariate survival analysis. Bioinformatics 30:1630–1632. doi:10.1093/bioinformatics/btu087